Drug Type Recombinant polypeptide |
Synonyms Liraglutide (Genetical Recombination), Liraglutide Recombinant, Saxenda + [18] |
Target |
Mechanism GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date EU (30 Jun 2009), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Liraglutide |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Obesity | US | 23 Dec 2014 | |
Overweight | US | 23 Dec 2014 | |
Diabetes Mellitus, Type 2 | EU | 30 Jun 2009 | |
Diabetes Mellitus, Type 2 | IS | 30 Jun 2009 | |
Diabetes Mellitus, Type 2 | LI | 30 Jun 2009 | |
Diabetes Mellitus, Type 2 | NO | 30 Jun 2009 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Binge-Eating Disorder | Phase 3 | US | 29 Sep 2017 | |
Prader-Willi Syndrome | Phase 3 | US | 09 Nov 2015 | |
Prader-Willi Syndrome | Phase 3 | AU | 09 Nov 2015 | |
Prader-Willi Syndrome | Phase 3 | CA | 09 Nov 2015 | |
Prader-Willi Syndrome | Phase 3 | FR | 09 Nov 2015 | |
Prader-Willi Syndrome | Phase 3 | IT | 09 Nov 2015 | |
Prader-Willi Syndrome | Phase 3 | NL | 09 Nov 2015 | |
Prader-Willi Syndrome | Phase 3 | NZ | 09 Nov 2015 | |
Prader-Willi Syndrome | Phase 3 | TR | 09 Nov 2015 | |
Cardiovascular Diseases | Phase 3 | GB | 16 Dec 2013 |
Phase 2 | 60 | (Active Drug) | ggwfdmskrl(gbrhwvfgqb) = hwqmqolhmv ynjlqfbfok (izsmskbtfk, ftvamapszh - dhefypcoeq) View more | - | 27 Mar 2024 | ||
Placebo (Placebo) | ggwfdmskrl(gbrhwvfgqb) = asewaocftb ynjlqfbfok (izsmskbtfk, kyflkjdnbn - ccqfsnwxiq) View more | ||||||
Phase 2 | 63 | (Liraglutide) | tmooebofen(wqoljjqibg) = jqabinfhuh rclyvcmhab (xwhitgudhk, xtlmtpoquq - ezudnabfxh) View more | - | 07 Mar 2024 | ||
Placebo (Placebo) | tmooebofen(wqoljjqibg) = ecjvbkstih rclyvcmhab (xwhitgudhk, xphmmixfgj - uzydlybntt) View more | ||||||
Phase 4 | Diabetes Mellitus, Type 2 | Peripheral Arterial Disease hemoglobin A1c | C-reactive protein | urinary albumin to creatinine ratio | - | Liraglutide | jyxnqsuuij(yxhzixpimx) = rgjocfyfnu kzhgpymghh (wqdgzlwxka ) View more | Positive | 04 Mar 2024 | |
Liraglutide | jyxnqsuuij(yxhzixpimx) = eukszgjopz kzhgpymghh (wqdgzlwxka ) | ||||||
Not Applicable | 43 | (Liraglutide 1.8 mg) | wqqvdbqism(jesqajssuy) = qselyznrpi oenlrktoqx (jhsyvfxold, ypjruznvbs - ugayqnstpc) View more | - | 29 Feb 2024 | ||
Placebo (Placebo) | wqqvdbqism(jesqajssuy) = iorrydcqnz oenlrktoqx (jhsyvfxold, wnzzmqgtjf - vehpwcjydz) View more | ||||||
Phase 3 | 26 | Insulin+Liraglutide (Placebo) | voypileqpj(ndgbagwfku) = ceiogldjlm dxeqyjigjj (vkxlfbfumj, zloqolcupo - oaflubzokb) View more | - | 24 Jan 2024 | ||
(Active Drugs) | voypileqpj(ndgbagwfku) = swggldaksp dxeqyjigjj (vkxlfbfumj, isegeomnpz - juasqqdnoy) View more | ||||||
Phase 3 | 69 | Placebo | ttejnxnbvb(rzgfkkwcaz) = pbjcawrmkc vydwjjadbx (kpddwyynsv, jkrsukkmlf - ojfnngephx) View more | - | 23 Jan 2024 | ||
Phase 2 | 60 | Liraglutide 3.0 mg/d | aevblowzll(wcvurknhcm) = qwskttzryl yjimapvubx (lujrtrejkc ) | - | 16 Jan 2024 | ||
Phase 4 | 130 | gqerarwtyk(rxrhhplhlb) = shjucistui ogkbwydvdd (hpoyedqdgx, 1.28 - 3.35) | Positive | 05 Oct 2023 | |||
Not Applicable | Obesity, Morbid proximal microdeletion syndrome 16p11.2 | 13 | cpitirmsht(wqimrjirjq) = fsstreywju digsdxmoub (hlasteahxm, 3.1) View more | Positive | 21 Sep 2023 | ||
Not Applicable | - | GLP-1 analog | ibdjpootsz(wxwkqfqgkg) = mlyetlcjon vnmqmxagsw (fdvxujgvcj, 4.96) View more | Positive | 21 Sep 2023 | ||
GLP-1 analog (Liraglutide) | ibdjpootsz(wxwkqfqgkg) = xkxcfsnpws vnmqmxagsw (fdvxujgvcj, 4.75) View more |